Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Fourth Quarter Earnings

  Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014   Fourth Quarter Earnings  Business Wire  NEW YORK -- April 1, 2014  Forest Laboratories, Inc. (NYSE:FRX), a leading fully integrated, specialty pharmaceutical company largely focused on the United States market, will release its Fiscal 2014 Fourth Quarter financial results before the U.S. stock market opens on Tuesday, April 29, 2014. At 10:00 AM EDT, Forest will host a conference call to discuss the financial results and relevant company and industry topics.  The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website www.FRX.com. Please log on to the website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until May 28, 2014 at both websites and also by dialing (800) 283-7928 (US and Canada) or (402) 220-0866 (international), Conference Call ID # FRXQ414.  About Forest Laboratories and Its Products  Forest Laboratories (NYSE: FRX) is a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market. The Company markets a portfolio of branded drug products and develops new medicines to treat patients suffering from diseases principally in five therapeutic areas: central nervous system, cardiovascular, gastrointestinal, respiratory, anti-infective and cystic fibrosis. Our strategy of acquiring product rights for development and commercialization through licensing, collaborative partnerships and targeted mergers and acquisitions allows us to take advantage of attractive late-stage development and commercial opportunities, thereby managing the risks inherent in drug development. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.  This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.  Contact:  Forest Laboratories, Inc. Frank J. Murdolo Vice President - Investor Relations, 1-212-224-6713 investor.relations@frx.com or Amanda Kaufman Senior Manager Corporate Communications and Media Relations, amanda.kaufman@frx.com  
Press spacebar to pause and continue. Press esc to stop.